It's clear from this latest interview that Tacti-003 is our...

It's clear from this latest interview that Tacti-003 is our first route to registration. Marc mentions that FDA fast track in 1st line head and neck means that it is potentially a registration trial if the results are good enough. The start of this trial can't come soon enough.
AIPAC will be a more costly path to registration if we have to go it alone but the rewards are potentially higher in this indication. Also, having two registrational trials running simultaneously is a lot less risky from an investor point of view, meaning funding will be less of problem. Combine that with IMP 761 in first trial in mid 2023(aprox), the company could look very attractive to investors by then with the first Tacit-003 results due around the same time.
There's also the (not so)small matter of Tacti-002 NSCLC trial. Will we get fast track in this indication too? I think there's a good chance given early results. That would change everything.
Fascinating 18 month period ahead with all our major programs